A new report says private equity firms are increasingly using joint ventures with nonprofit health systems to expand in healthcare, drawing calls for greater oversight. The investigation highlights nonprofit partnership structures as a less visible mechanism for capital expansion—outside traditional acquisition headlines. The push for enhanced scrutiny matters for biotech-adjacent stakeholders because ownership and governance structures can influence clinical service distribution, contracting behavior, and the adoption pace of new diagnostics and therapeutics. The report adds to the policy and governance debate around how healthcare capital flows affect patient access and health system decision-making, particularly where biotech supply chains and reimbursement incentives intersect.